Valcyte (valganciclovir) - Roche, Tanabe Pharma
Prevymis (letermovir) - Merck (MSD)
Breakthrough CMV Infection Due to de Novo Letermovir Resistance in a Kidney Transplant Recipient: A Case Report. (PubMed, Transplant Proc) - May 23, 2026 - "Few articles discussed the clinical significance of letermovir resistance, especially in transplant recipients with breakthrough viremia. In this case report, we describe a rare de novo letermovir resistance in a kidney transplant patient, requiring a switch to valganciclovir." 
Journal • Bone Marrow Transplantation • Cytomegalovirus Infection • Hematological Disorders • Infectious Disease • Solid Organ Transplantation • Transplantation
http://www.ncbi.nlm.nih.gov/pubmed/42173702
 
Abd Assalam Qannus; Fariba Donovan; Muzammeel Hada
 
May 23, 2026
 
Prev Next